{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:01:08Z","timestamp":1792598468350,"version":"4.5.0"},"reference-count":103,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.phrs.2022.106261","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T18:05:25Z","timestamp":1652724325000},"page":"106261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications"],"prefix":"10.1016","volume":"181","author":[{"given":"Konstantinos","family":"Arvanitakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theocharis","family":"Koufakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalliopi","family":"Kotsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Germanidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2022.106261_bib1","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.phrs.2022.106261_bib2","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","article-title":"The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015","volume":"3","author":"Global Burden of Disease Liver Cancer","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.phrs.2022.106261_bib3","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","article-title":"Hepatocellular carcinoma in cirrhosis: incidence and risk factors","volume":"127","author":"Fattovich","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2022.106261_bib4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cld.2017.08.014","article-title":"Nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis and hepatocellular carcinoma","volume":"22","author":"Massoud","year":"2018","journal-title":"Clin. Liver Dis."},{"key":"10.1016\/j.phrs.2022.106261_bib5","doi-asserted-by":"crossref","first-page":"HEP41","DOI":"10.2217\/hep-2021-0003","article-title":"Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma","volume":"9","author":"Ronnebaum","year":"2022","journal-title":"Hepat. Oncol."},{"key":"10.1016\/j.phrs.2022.106261_bib6","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.phrs.2022.106261_bib7","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/ndt\/gfl175","article-title":"Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes--results of a hyperglycaemic glucose clamp study","volume":"21","author":"Rave","year":"2006","journal-title":"Nephrol. Dial. Transpl."},{"key":"10.1016\/j.phrs.2022.106261_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000503919","article-title":"The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis","volume":"10","author":"Lo","year":"2020","journal-title":"Cardiorenal Med."},{"key":"10.1016\/j.phrs.2022.106261_bib9","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.2337\/dc22-S010","article-title":"Cardiovascular disease and risk management: standards of medical care in diabetes-2022","volume":"45","author":"American Diabetes Association Professional Practice","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.phrs.2022.106261_bib10","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s11096-021-01256-9","article-title":"Sodium-glucose co-transporter 2 inhibitors in COVID-19: meeting at the crossroads between heart, diabetes and infectious diseases","volume":"43","author":"Koufakis","year":"2021","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.phrs.2022.106261_bib11","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options","volume":"1","author":"Gastaldelli","year":"2019","journal-title":"JHEP Rep."},{"key":"10.1016\/j.phrs.2022.106261_bib12","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1530\/EC-20-0490","article-title":"Pathophysiology of NASH in endocrine diseases","volume":"10","author":"Gariani","year":"2021","journal-title":"Endocr. Connect"},{"key":"10.1016\/j.phrs.2022.106261_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13231","article-title":"The role of autoimmunity in the pathophysiology of type 2 diabetes: Looking at the other side of the moon","volume":"22","author":"Koufakis","year":"2021","journal-title":"Obes. Rev."},{"key":"10.1016\/j.phrs.2022.106261_bib14","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/hepr.13645","article-title":"Meta-analysis of the effect of sodium-glucose cotransporter 2 inhibitors on hepatic fibrosis in patients with type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease","volume":"51","author":"Song","year":"2021","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.phrs.2022.106261_bib15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diabet.2019.01.008","article-title":"Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications","volume":"45","author":"Scheen","year":"2019","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.phrs.2022.106261_bib16","first-page":"13","article-title":"Tumor-associated neutrophils in hepatocellular carcinoma pathogenesis, prognosis, and therapy","author":"Arvanitakis","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2022.106261_bib17","first-page":"14","article-title":"Tumor-associated macrophages in hepatocellular carcinoma pathogenesis, prognosis and therapy","author":"Arvanitakis","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2022.106261_bib18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41575-019-0145-7","article-title":"From NASH to HCC: current concepts and future challenges","volume":"16","author":"Anstee","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2022.106261_bib19","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.23527","article-title":"The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis","volume":"51","author":"Ascha","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2022.106261_bib20","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4254\/wjh.v9.i11.533","article-title":"Hepatocellular carcinoma in non-alcoholic steatohepatitis: current knowledge and implications for management","volume":"9","author":"Cholankeril","year":"2017","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.phrs.2022.106261_bib21","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41590-018-0044-z","article-title":"The immunology of hepatocellular carcinoma","volume":"19","author":"Ringelhan","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.phrs.2022.106261_bib22","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/1471-2350-11-172","article-title":"Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease","volume":"11","author":"Hotta","year":"2010","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.phrs.2022.106261_bib23","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.3748\/wjg.v19.i41.6969","article-title":"PNPLA3 I148M polymorphism and progressive liver disease","volume":"19","author":"Dongiovanni","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.phrs.2022.106261_bib24","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ccr.2012.02.007","article-title":"Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4","volume":"21","author":"Dapito","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2022.106261_bib25","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1007\/s10620-010-1447-3","article-title":"Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8","volume":"56","author":"Shanab","year":"2011","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.phrs.2022.106261_bib26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrgastro.2015.94","article-title":"Inflammasome activation and function in liver disease","volume":"12","author":"Szabo","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2022.106261_bib27","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ccell.2014.09.003","article-title":"Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes","volume":"26","author":"Wolf","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2022.106261_bib28","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nature24302","article-title":"Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity","volume":"551","author":"Shalapour","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2022.106261_bib29","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2022.106261_bib30","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1097\/COC.0000000000000388","article-title":"Obesity is independently associated with increased risk of hepatocellular cancer-related mortality: a systematic review and meta-analysis","volume":"41","author":"Gupta","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2022.106261_bib31","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease","volume":"75","author":"Ipsen","year":"2018","journal-title":"Cell Mol. Life Sci."},{"key":"10.1016\/j.phrs.2022.106261_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097136","article-title":"HCC development is associated to peripheral insulin resistance in a mouse model of NASH","volume":"9","author":"De Minicis","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2022.106261_bib33","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1002\/hep.22856","article-title":"Overexpression of insulin receptor substrate-1 and hepatitis Bx genes causes premalignant alterations in the liver","volume":"49","author":"Longato","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2022.106261_bib34","first-page":"11","article-title":"Wnt\/beta-catenin signaling in liver","author":"Wang","year":"2019","journal-title":"Cancers Cancers"},{"key":"10.1016\/j.phrs.2022.106261_bib35","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1038\/s41598-021-82252-x","article-title":"Inhibition of androgen\/AR signaling inhibits diethylnitrosamine (DEN) induced tumour initiation and remodels liver immune cell networks","volume":"11","author":"Helms","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2022.106261_bib36","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/hep.24774","article-title":"Cell cycle-related kinase links androgen receptor and beta-catenin signaling in hepatocellular carcinoma: why are men at a loss?","volume":"55","author":"Awuah","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2022.106261_bib37","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1172\/JCI45967","article-title":"Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives beta-catenin\/T cell factor-dependent hepatocarcinogenesis","volume":"121","author":"Feng","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2022.106261_bib38","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/ni.3659","article-title":"Postprandial macrophage-derived IL-1beta stimulates insulin, and both synergistically promote glucose disposal and inflammation","volume":"18","author":"Dror","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.phrs.2022.106261_bib39","first-page":"R229","article-title":"Cytokine signaling during myocardial infarction: sequential appearance of IL-1 beta and IL-6","volume":"269","author":"Guillen","year":"1995"},{"key":"10.1016\/j.phrs.2022.106261_bib40","first-page":"1119","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017"},{"key":"10.1016\/j.phrs.2022.106261_bib41","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9944880","article-title":"Anti-inflammatory effects of empagliflozin and gemigliptin on LPS-stimulated macrophage via the IKK\/NF-kappaB, MKK7\/JNK, and JAK2\/STAT1 signalling pathways","volume":"2021","author":"Lee","year":"2021","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.phrs.2022.106261_bib42","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ebiom.2019.07.027","article-title":"Inflammatory and immunometabolic consequences of gut dysfunction in HIV: parallels with IBD and implications for reservoir persistence and non-AIDS comorbidities","volume":"46","author":"Jehad","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.phrs.2022.106261_bib43","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.02242","article-title":"Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis","volume":"3","author":"Wheaton","year":"2014","journal-title":"Elife"},{"key":"10.1016\/j.phrs.2022.106261_bib44","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the american association for the study of liver diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2022.106261_bib45","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.phrs.2022.106261_bib46","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ejca.2011.12.021","article-title":"EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma","volume":"48","author":"European Association for Study of","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.phrs.2022.106261_bib47","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1111\/jgh.15202","article-title":"The impact of sodium glucose co-transporter 2 inhibitors on non-alcoholic fatty liver disease","volume":"36","author":"Chrysavgis","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.phrs.2022.106261_bib48","doi-asserted-by":"crossref","first-page":"172","DOI":"10.2174\/1570161117666190405164313","article-title":"Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block","volume":"18","author":"Athyros","year":"2020","journal-title":"Curr. Vasc. Pharm."},{"key":"10.1016\/j.phrs.2022.106261_bib49","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/jdi.13237","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials","volume":"11","author":"Xing","year":"2020","journal-title":"J. Diabetes Invest."},{"key":"10.1016\/j.phrs.2022.106261_bib50","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s10620-019-5477-1","article-title":"Empagliflozin for the treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus","volume":"65","author":"Lai","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.phrs.2022.106261_bib51","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.2169\/internalmedicine.8754-16","article-title":"The improvement of the hepatic histological findings in a patient with non-alcoholic steatohepatitis with type 2 diabetes after the administration of the sodium-glucose cotransporter 2 inhibitor ipragliflozin","volume":"56","author":"Takeda","year":"2017","journal-title":"Intern Med."},{"key":"10.1016\/j.phrs.2022.106261_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151511","article-title":"Ipragliflozin improves hepatic steatosis in obese mice and liver dysfunction in type 2 diabetic patients irrespective of body weight reduction","volume":"11","author":"Komiya","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2022.106261_bib53","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2022.106261_bib54","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1007\/s12325-020-01498-5","article-title":"Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: a randomized, double-blind, placebo-controlled trial","volume":"37","author":"Taheri","year":"2020","journal-title":"Adv. Ther."},{"key":"10.1016\/j.phrs.2022.106261_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222413336","article-title":"Canagliflozin modulates hypoxia-induced metastasis, angiogenesis and glycolysis by decreasing HIF-1alpha protein synthesis via AKT\/mTOR pathway","volume":"22","author":"Luo","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2022.106261_bib56","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41419-019-1646-6","article-title":"Canagliflozin inhibits growth of hepatocellular carcinoma via blocking glucose-influx-induced beta-catenin activation","volume":"10","author":"Hung","year":"2019","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.phrs.2022.106261_bib57","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1038\/s41598-018-19658-7","article-title":"Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH","volume":"8","author":"Shiba","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2022.106261_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232283","article-title":"Effects of canagliflozin on growth and metabolic reprograming in hepatocellular carcinoma cells: Multi-omics analysis of metabolomics and absolute quantification proteomics (iMPAQT)","volume":"15","author":"Nakano","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2022.106261_bib59","first-page":"20","article-title":"The SGLT2 inhibitor canagliflozin prevents carcinogenesis in a mouse model of diabetes and non-alcoholic steatohepatitis-related hepatocarcinogenesis: association with SGLT2 expression in hepatocellular carcinoma","author":"Jojima","year":"2019","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2022.106261_bib60","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/ijc.31193","article-title":"Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake","volume":"142","author":"Kaji","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phrs.2022.106261_bib61","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.4103\/jcrt.JCRT_963_19","article-title":"Canagliflozin, a SGLT-2 inhibitor, relieves ER stress, modulates autophagy and induces apoptosis in irradiated HepG2 cells: Signal transduction between PI3K\/AKT\/GSK-3beta\/mTOR and Wnt\/beta-catenin pathways; in vitro","volume":"17","author":"Abdel-Rafei","year":"2021","journal-title":"J. Cancer Res Ther."},{"key":"10.1016\/j.phrs.2022.106261_bib62","first-page":"11","article-title":"Selective PPARalpha modulator pemafibrate and sodium-glucose cotransporter 2 inhibitor tofogliflozin combination treatment improved histopathology in experimental mice model of non-alcoholic steatohepatitis","author":"Murakami","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2022.106261_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111738","article-title":"The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model","volume":"140","author":"Yoshioka","year":"2021","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.phrs.2022.106261_bib64","doi-asserted-by":"crossref","first-page":"58353","DOI":"10.18632\/oncotarget.16874","article-title":"Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice","volume":"8","author":"Obara","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2022.106261_bib65","article-title":"Dapagliflozin alleviates hepatic steatosis by restoring autophagy via the AMPK-mTOR Pathway","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharm."},{"key":"10.1016\/j.phrs.2022.106261_bib66","first-page":"21","article-title":"Combined treatment with sodium-glucose cotransporter-2 inhibitor (Canagliflozin) and dipeptidyl peptidase-4 inhibitor (Teneligliptin) alleviates NASH progression in a non-diabetic rat model of steatohepatitis","author":"Ozutsumi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2022.106261_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106039","article-title":"Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials","volume":"175","author":"Benedetti","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.phrs.2022.106261_bib68","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1186\/1471-2407-14-985","article-title":"Serum glucose and risk of cancer: a meta-analysis","volume":"14","author":"Crawley","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.phrs.2022.106261_bib69","doi-asserted-by":"crossref","first-page":"E4111","DOI":"10.1073\/pnas.1511698112","article-title":"Functional expression of sodium-glucose transporters in cancer","volume":"112","author":"Scafoglio","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2022.106261_bib70","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00424-020-02448-4","article-title":"SGLT2 and cancer","volume":"472","author":"Wright","year":"2020","journal-title":"Pflug. Arch."},{"key":"10.1016\/j.phrs.2022.106261_bib71","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.381","article-title":"Obesity and cancer, a case for insulin signaling","volume":"6","author":"Poloz","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.phrs.2022.106261_bib72","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/liv.14048","article-title":"Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma","volume":"39","author":"Schulte","year":"2019","journal-title":"Liver Int."},{"key":"10.1016\/j.phrs.2022.106261_bib73","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.1038\/s41388-019-0942-z","article-title":"Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma","volume":"38","author":"Shankaraiah","year":"2019","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2022.106261_bib74","doi-asserted-by":"crossref","DOI":"10.1007\/s13679-022-00474-0","article-title":"Anti-obesity medications for the management of nonalcoholic fatty liver disease","author":"Polyzos","year":"2022","journal-title":"Curr. Obes. Rep."},{"key":"10.1016\/j.phrs.2022.106261_bib75","first-page":"21","article-title":"Glucagon-like peptide-1 receptor agonist prevented the progression of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis","author":"Kojima","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2022.106261_bib76","first-page":"12","article-title":"Statin use and the risk of hepatocellular carcinoma: a meta-analysis of observational studies","author":"Islam","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2022.106261_bib77","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1055\/s-0039-1679956","article-title":"Prevention of hepatocellular carcinoma by statins: clinical evidence and plausible mechanisms","volume":"39","author":"Kim","year":"2019","journal-title":"Semin Liver Dis."},{"key":"10.1016\/j.phrs.2022.106261_bib78","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2018.11.011","article-title":"p53 represses the mevalonate pathway to mediate tumor suppression","volume":"176","author":"Moon","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2022.106261_bib79","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s12072-011-9338-z","article-title":"Ascites in patients with hepatocellular carcinoma: prevalence, associated factors, prognostic impact, and staging strategy","volume":"7","author":"Hsu","year":"2013","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.phrs.2022.106261_bib80","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/gutjnl-2020-321790","article-title":"Guidelines on the management of ascites in cirrhosis","volume":"70","author":"Aithal","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2022.106261_bib81","first-page":"795","article-title":"SGLT2 inhibitors: a new dawn for recurrent\/refractory cirrhotic ascites","volume":"9","author":"Gao","year":"2021","journal-title":"J. Clin. Transl. Hepatol."},{"key":"10.1016\/j.phrs.2022.106261_bib82","doi-asserted-by":"crossref","first-page":"618","DOI":"10.14309\/ajg.0000000000000995","article-title":"Empagliflozin eliminates refractory ascites and hepatic hydrothorax in a patient with primary biliary cirrhosis","volume":"116","author":"Kalambokis","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.phrs.2022.106261_bib83","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: diuretic and cardiorenal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2022.106261_bib84","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1161\/CIRCULATIONAHA.120.048739","article-title":"Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the RECEDE-CHF trial","volume":"142","author":"Mordi","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2022.106261_bib85","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1253\/circrep.CR-20-0041","article-title":"Empagliflozin administration can decrease the dose of loop diuretics and prevent the exacerbation of renal tubular injury in patients with compensated heart failure complicated by diabetes","volume":"2","author":"Shirakabe","year":"2020","journal-title":"Circ. Rep."},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2022.106261_bib86","first-page":"S228","article-title":"Sodium glucose co-transporter 2 inhibitors do not increase the risk of hyperkaleamia in type 2 diabetes: a systematic review and meta-analysis","volume":"64","author":"Charlwood","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.phrs.2022.106261_bib87","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2022.106261_bib88","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1080\/17425255.2018.1551877","article-title":"The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments","volume":"14","author":"Garcia-Ropero","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.phrs.2022.106261_bib89","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1111\/dom.14470","article-title":"Sodium-glucose cotransporter-2 inhibitors for type 2 diabetes mellitus in adults: an overview of 46 systematic reviews","volume":"23","author":"Augusto","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2022.106261_bib90","article-title":"Sodium-glucose Co-transporter 2 inhibitors for non-alcoholic fatty liver disease in asian patients with type 2 diabetes: a meta-analysis","volume":"11","author":"Wong","year":"2020","journal-title":"Front Endocrinol."},{"key":"10.1016\/j.phrs.2022.106261_bib91","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/dom.12183","article-title":"Pharmacokinetics, safety and tolerability of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with hepatic impairment","volume":"16","author":"Macha","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2022.106261_bib92","doi-asserted-by":"crossref","unstructured":"Bhatt, D.L.; Szarek, M.; Pitt, B.; Cannon, C.P.; Leiter, L.A.; McGuire, D.K.; Lewis, J.B.; Riddle, M.C.; Inzucchi, S.E.; Kosiborod, M.N.; et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. 2020, 384, 129\u2013139, doi:10.1056\/NEJMoa2030186.","DOI":"10.1056\/NEJMoa2030186"},{"key":"10.1016\/j.phrs.2022.106261_bib93","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3109\/08830185.2014.889129","article-title":"The role of the liver in sepsis","volume":"33","author":"Yan","year":"2014","journal-title":"Int. Rev. Immunol."},{"issue":"Suppl 2","key":"10.1016\/j.phrs.2022.106261_bib94","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/dom.13611","article-title":"A safety update on sodium glucose co-transporter 2 inhibitors","volume":"21","author":"Fitchett","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2022.106261_bib95","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1038\/ki.2010.512","article-title":"Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans","author":"List","year":"2011","journal-title":"Kidney Int. Suppl."},{"key":"10.1016\/j.phrs.2022.106261_bib96","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1111\/bcp.14800","article-title":"Intestinal SGLT1 as a therapeutic target in COVID-19-related diabetes: a \u201ctwo-edged sword\u201d hypothesis","volume":"87","author":"Koufakis","year":"2021","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.phrs.2022.106261_bib97","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S2213-8587(21)00180-7","article-title":"Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Kosiborod","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2022.106261_bib98","doi-asserted-by":"crossref","first-page":"HEP27","DOI":"10.2217\/hep-2020-0024","article-title":"Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review","volume":"7","author":"Aly","year":"2020","journal-title":"Hepat. Oncol."},{"key":"10.1016\/j.phrs.2022.106261_bib99","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/jcpt.13107","article-title":"The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: Is the risk worth taking?","volume":"45","author":"Koufakis","year":"2020","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.phrs.2022.106261_bib100","doi-asserted-by":"crossref","first-page":"m4147","DOI":"10.1136\/bmj.m4147","article-title":"Diabetic ketoacidosis with SGLT2 inhibitors","volume":"371","author":"Musso","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2022.106261_bib101","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2174\/1381612826666200909142126","article-title":"Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors on cardiorenal and metabolic outcomes in people without diabetes","volume":"27","author":"Papazafiropoulou","year":"2021","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.phrs.2022.106261_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105872","article-title":"Looking deeper into the findings of DARE-19: failure or an open door to future success?","volume":"173","author":"Koufakis","year":"2021","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2022.106261_bib103","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","author":"Voors","year":"2022","journal-title":"Nat. Med."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822002067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822002067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:31:57Z","timestamp":1760913117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822002067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":103,"alternative-id":["S1043661822002067"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106261","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106261","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106261"}}